Skip to content

A novel kinase degrader antibody conjugate for the treatment of mCRPC

Joost C.M. Uitdehaag, Jos de Man, Freek van Cauter, Sander P.W. van Gemert, Milan J. Hoffmann, Yvonne G.T.H. van Mil, Winfried R. Mulder, Michelle Muller, Martine B.W. Prinsen, Jan Gerard Sterrenburg, Diep Vu,
Joeri J.P. de Wit, Erik Ensing, Rogier C.

23 May 2025|

A rationally designed cell cycle kinase degrader as a novel payload for ADCs

Joost C.M. Uitdehaag, Winfried R. Mulder, Freek van Cauter, Sander P.W. van Gemert, Milan J. Hoffmann, Yvonne G.T.H. van Mil, Daphne Montizaan, Michelle Muller, Martine B.W. Prinsen, Jan Gerard Sterrenburg, Diep Vu, Joeri J.P. de Wit, Jos de Man, Erik

31 March 2025|

A novel kinase degrader-based payload for the development of potent Degrader Antibody Conjugates (DACs)

Joost C.M. Uitdehaag, Yvonne G.T.H. van Mil, Freek van Cauter, Sander P.W. van Gemert, Milan J. Hoffmann, Winfried R. Mulder,
Michelle Muller, Martine B.W. Prinsen, Jan Gerard Sterrenburg, Diep Vu, Joeri J.P. de Wit, Jos de Man, Erik Ensing, Rogier C.

13 November 2024|

CFON-026, a best-in-class macrocyclic non-covalent BTK inhibitor targeting WT and all clinically relevant mutant variants

Yvonne G.T.H. van Mil, Joost C.M. Uitdehaag, Freek van Cauter, Sander P.W. van Gemert, Milan J. Hoffmann, Michelle Muller, Winfried R. Mulder, Martine B.W. Prinsen, Jan Gerard Sterrenburg, Diep Vu, Joeri J.P. de Wit, Jos de Man, Erik Ensing, Rogier

13 November 2024|

Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination

Elisa Zanini, Nicole Forster-Gross, Felix Bachmann, Adrian Brüngger, Paul McSheehy, Karine Litherland, Karin Burger, Anna C. Groner, Mila Roceri, Luc Bury, Martin Stieger, Nicole Willemsen-Seegers, Jos de Man, Diep Vu-Pham, Helma W. E. van Riel, Guido J. R. Zaman, Rogier

13 August 2024|

EPriL Macrocycles as a Platform for the Rapid Generation of Effective Kinase Degraders, for Use in Antibody Conjugates

Joost C.M. Uitdehaag, Jos de Man, Michelle Muller, Freek van Cauter, Sander P.W. van Gemert, Milan J. Hoffmann, Yvonne G.T.H. van Mil, Winfried R. Mulder, Martine B.W. Prinsen, Jan Gerard Sterrenburg, Diep Vu, Joeri J.P. de Wit, Erik Ensing, Rogier

19 April 2024|

EPriL: a Platform for the Rapid Identification of Degraders of Clinically Relevant BTK Mutants

Michelle Muller, Jos de Man, Joost C.M. Uitdehaag, Freek van Cauter, Sander P.W. van Gemert, Milan J. Hoffmann, Yvonne G.T.H. van Mil, Winfried R. Mulder, Martine B.W. Prinsen, Rik C.P.A. Remmers, Jan Gerard Sterrenburg, Diep Vu, Joeri J.P. de Wit,

19 April 2024|

CFON-026, a Best-In-Class Macrocyclic Non-Covalent Inhibitor of BTK WT and BTK Resistance Mutations

Jos de Man, Michelle Muller, Joost C.M. Uitdehaag, Freek van Cauter, Sander P.W. van Gemert, Milan J. Hoffmann, Yvonne G.T.H. van Mil,
Winfried R. Mulder, Martine B.W. Prinsen, Jan Gerard Sterrenburg, Diep Vu, Joeri J.P. de Wit, Erik Ensing, Rogier C.

19 April 2024|

LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma

Caitlin B. Conboy, Jennifer A. Yonkus, EeeLN H. Buckarma, Dong-Gi Mun, Nathan W. Werneburg, Ryan D. Watkins, Roberto Alva-Ruiz, Jennifer L. Tomlinson, Yi Guo, Juan Wang, Daniel O’Brien, Chantal E. McCabe, Erik Jessen, Rondell P. Graham, Rogier C. Buijsman, Diep

19 April 2024|

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017

Joost C.M. Uitdehaag, Jeffrey J. Kooijman, Jeroen A.D.M. de Roos, Martine B.W. Prinsen, Jelle Dylus, Nicole Willemsen-Seegers,Yusuke Kawase, Masaaki Sawa, Jos de Man, Suzanne J.C. van Gerwen, Rogier C. Buijsman, and Guido J.R. Zaman. Molecular Cancer Therapeutics. 2019

15 August 2023|
12Next

info@crossfire-oncology.com

Privacy Policy
Disclaimer

Page load link
  • Crossfire Oncology
  • About us
  • Science
  • Pipeline
    • TTK/PLK1 inhibitor (BAL0891)
    • BTK inhibitor (CFON-026)
  • Working at Crossfire
  • News
  • Publications